Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors

Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors

BackgroundThe association between hematologic parameters and anti-programmed death-1 (PD-1) inhibitors was generally examined without considering therapy lines and medicine types. The study was aimed to identify potential hematologic biomarkers associated with clinical outcome in patients with non-s...

Full description

Bibliographic Details
Main Authors: Xinmin Zhao, Xianghua Wu, Hui Yu, Huijie Wang, Si Sun, Zhihuang Hu, Cuicui Liu, Junli Zhang, Yang Shao, Jialei Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
hematologic parameters
prognosis
first-line pembrolizumab
subsequent-line
nivolumab
NSCLC
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1003581/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1003581/full

Similar Items